MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
6.88
+0.74
+11.97%
Opening 13:23 04/01 EDT
OPEN
6.17
PREV CLOSE
6.14
HIGH
7.00
LOW
6.17
VOLUME
786.19K
TURNOVER
--
52 WEEK HIGH
13.53
52 WEEK LOW
3.180
MARKET CAP
374.05M
P/E (TTM)
-1.2713
1D
5D
1M
3M
1Y
5Y
1D
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday
Benzinga · 2h ago
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 5h ago
Weekly Report: what happened at ALMS last week (0324-0328)?
Weekly Report · 1d ago
Alumis Inc. Reports 2024 Results and Strategic Merger
TipRanks · 5d ago
Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.
TipRanks · 6d ago
Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreement
TipRanks · 6d ago
What's Going On With Alumis Shares Tuesday?
Benzinga · 03/25 15:54
BUZZ-Alumis jumps on licensing deal for skin drug
Reuters · 03/25 15:25
More
About ALMS
More
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Recently
Symbol
Price
%Change

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.